Evidence map›Paper›PMID 37899754›Full record

ArticleAmerican journal of physiology. Regulatory, integrative and comparative physiology2024

Pseudocannabinoid H4CBD improves glucose response during advanced metabolic syndrome in OLETF rats independent of increase in insulin signaling proteins.

Jessica N Wilson, Dora A Mendez, Francis Dhoro, Nikolay Shevchenko, Mark Mascal, Kyle Lund, Robert Fitzgerald, Nicholas V DiPatrizio, Rudy M Ortiz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Regulatory, integrative and comparative physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jessica N WilsonDepartment of Molecular and Cell Biology, School of Natural Sciences, University of California, Merced, California, United States.ORCID 0000-0001-5169-2359
Dora A MendezDepartment of Molecular and Cell Biology, School of Natural Sciences, University of California, Merced, California, United States.ORCID 0000-0001-9209-8225
Francis DhoroDepartment of Chemistry, University of California, Davis, California, United States.
Nikolay ShevchenkoDepartment of Chemistry, University of California, Davis, California, United States.
Mark MascalDepartment of Chemistry, University of California, Davis, California, United States.
Kyle LundDepartment of Pathology, University of California, San Diego, California, United States.
Robert FitzgeraldDepartment of Pathology, University of California, San Diego, California, United States.
Nicholas V DiPatrizioDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, California, United States.
Rudy M OrtizDepartment of Molecular and Cell Biology, School of Natural Sciences, University of California, Merced, California, United States.ORCID 0000-0003-3715-7194

Funding

UC | UCSD | Center for Medicinal Cannabis Research, University of California, San Diego (CMCR, UCSD) A21-0086
6 · The paper itself

Abstract

Cannabidiol (CBD) use has grown exponentially more popular in the last two decades, particularly among older adults (>55 yr), though very little is known about the effects of CBD use during age-associated metabolic dysfunction. In addition, synthetic analogues of CBD have generated great interest because they can offer a chemically pure product, which is free of plant-associated contaminants. To assess the effects of a synthetic analogue of CBD (H4CBD) on advanced metabolic dysfunction, a cohort of 41-wk-old Otsuka Long-Evans Tokushima Fatty (OLETF) rats were administered 200 mg H4CBD/kg by oral gavage for 4 wk. Animals were fed ad libitum and monitored alongside vehicle-treated OLETF and Long-Evans Tokushima Otsuka (LETO) rats, the lean-strain controls. An oral glucose-tolerance test (oGTT) was performed after 4 wk of treatment. When compared with vehicle-treated, OLETF rats, H4CBD decreased body mass (BM) by 15%, which was attributed to a significant loss in abdominal fat. H4CBD reduced glucose response (AUC

Indexed as

CannabidiolDiabetes Mellitus, Type 2Metabolic SyndromeAgedAnimalsBlood GlucoseGlucoseHumansInsulinRatsRats, Inbred OLETFRats, Long-EvansBlood GlucoseCannabidiolGlucoseInsulinadiponectinghrelinleptinobesitytype II diabetes mellitus

Identifiers

PMID37899754
PMCPMC11283894

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.